Shots:
- Ono has entered into a drug discovery partnership & option agreement with Mediar Therapeutics to develop novel antibody therapeutics for fibro-inflammatory diseases
- As per the deal, Mediar will conduct research using its fibrosis-focused research platform, while Ono will gain exclusive worldwide option rights to select candidates for development, manufacturing, & commercialization
- The partnership will strengthen Ono’s immunology & inflammation pipeline while combining Mediar’s fibrosis expertise to advance innovative biologics for diseases with high unmet medical need
Ref: Businesswire | Image: Ono & Mediar | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
